In a 96-h WST-1 assay across 12 canine tumor cell lines, gedatolisib had IC50 values below 1 µM in 10 lines. Responses varied substantially, and the study did not establish efficacy or tolerability in dogs. [1]
Across 28 breast-cancer cell lines treated for 72 h, gedatolisib produced an average GR50 of 12 nM and GRMax of −0.68. Its average growth-rate response exceeded those of alpelisib, capivasertib and everolimus in this panel; these cellular metrics do not establish comparative clinical efficacy. [2]
Canine tumor-cell viability panel
Cell-based study · 12 canine cell lines from six tumor types: POS, HMPOS, MCTCC, LCTCC, MegTCC, MomoTCC, CMeC, MCM-N1, DH82, CHS-4, CoMS and CLAC. [1]
Gedatolisib reduced the WST-1 viability endpoint; IC50 values were <1 µM in 10 of 12 lines. Sensitivity was heterogeneous. CLAC was below 50% viability even at the lowest tested concentration, and its plotted IC50 was a boundary placeholder rather than an exact fitted potency.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.1 nM–10 µM
- Exposure duration
- 96 h
- Method
- WST-1 absorbance assay
- Vehicle
- 0.1% DMSO control
- Reported limits
- Five replicates are reported; independent-experiment versus well-level replication is not specified in the caption.
Methods and source locations
Compound reported in the paper: Gedatolisib (PKI-587); Compound label in the paper: gedatolisib
Evidence for the named active compound in the stated model and formulation; no Adooq lot validation or salt/form conversion.
Figure 2A–B and caption; Methods: Inhibitors, Cell viability assay, Statistical analysis; Results: Gedatolisib decreases cell viability
Cell viability after 96 h: Three-parameter variable-slope sigmoidal dose-response fitting; Figure 2A reports mean ± SD of five replicates. — Figure 2A–B and caption; Results first subsection
Differential cellular PI3K/mTOR pathway suppression
Cell-based study · Canine transitional-cell carcinoma lines MegTCC and LCTCC. [1]
After 24 h, dose-dependent loss of Akt, 4E-BP1 and p70S6K phosphorylation and increased p27Kip1 were reported in MegTCC; comparable sustained changes were not detected in LCTCC. This is cellular pathway evidence, not a direct enzyme-binding or selectivity assay.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 nM–10 µM shown in Figure 4A, plus zero-dose control
- Exposure duration
- 24 h
- Method
- Immunoblotting of phosphorylated and total proteins with β-actin loading control
- Vehicle
- 0.1% DMSO
- Reported limits
- Blot replication not specified in the adopted caption; no quantitative band-effect sizes reported.
Methods and source locations
Compound reported in the paper: Gedatolisib (PKI-587); Compound label in the paper: gedatolisib
Evidence for the named active compound in the stated model and formulation; no Adooq lot validation or salt/form conversion.
Figure 4A and caption; Methods: Inhibitors and Immunoblotting; Results: Gedatolisib inhibits the phosphorylation
Akt (Ser473), 4E-BP1 (Thr37/46), p70S6K (Thr389) phosphorylation and p27Kip1 expression: Phosphorylated/total protein and β-actin bands; no densitometric estimates extracted. — Figure 4A; corresponding Results paragraph
Growth-rate response across breast-cancer cell lines
Cell-based study · 28 human breast-cancer cell lines with varied PIK3CA/PTEN and ER/HER2 status. [2]
Gedatolisib had an average GR50 of 12 nM and average GRMax of −0.68 across the panel after 72 h. It was more potent and efficacious on average than alpelisib, capivasertib and everolimus in this assay. These are growth-rate metrics, not biochemical IC50 values.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1.4–9000 nM
- Exposure duration
- 72 h
- Method
- RT-Glo MT before and after treatment; proliferation-normalized growth-rate analysis
- Vehicle
- Matched DMSO control
- Reported limits
- Figure 1c reports n=2 biologically independent samples; no whole-panel biological replication count is assigned here beyond the caption.
Methods and source locations
Compound reported in the paper: Gedatolisib (PKI-587); Compound label in the paper: gedatolisib
Evidence for the named active compound in the stated model and formulation; no Adooq lot validation or salt/form conversion.
Figure 1c–f, especially table 1e; Results: Analysis of PAM inhibitors response; Methods: Treatments, Viability and cell death, GR assays
Concentration yielding normalized growth-rate value 0.5 across 28 cell lines: Pre/post-treatment viability and growth-rate curve fitting. — Results first subsection; Figure 1e average row
Normalized growth rate at maximum tested concentration: Negative GR values denote cytotoxicity; pooled panel average, not a percent viability. — Figure 1e average row; Methods: GR assays